Predict your next investment

HEALTHCARE | Drug Development
coherus.com

See what CB Insights has to offer

Founded Year

2010

Stage

Corporate Minority - P2P | IPO

Total Raised

$143.23M

Market Cap

1.07B

Stock Price

13.90

Revenue

$0000 

About Coherus BioSciences

Coherus is a biologics platform company fthat focuses on delivering biosimilar therapeutics that will expand patient access to medications worldwide. Coherus develops a collaborative business model that leverages a strategic consortium of service providers aligned through ownership and shared incentives. Coherus' global commercialization partnerships include top-tier biopharma companies in Europe, Asia, and Latin America.

Coherus BioSciences Headquarter Location

333 Twin Dolphin Drive Suite 600

Redwood City, California, 94065,

United States

650-649-3530

Latest Coherus BioSciences News

Junshi Biosciences starts 2022 with two licensing deals

Jan 11, 2022

Jan. 11, 2022 Barely two weeks into the year, Shanghai Junshi Biosciences Co. Ltd. has already locked down an out-licensing deal and an in-licensing agreement. In a follow-up to their $1.1 billion deal a year ago, Coherus Biosciences Inc. has moved ahead with the right to exercise its option to license Junshi’s JS-006, a recombinant humanized IgG4k monoclonal antibody targeting T cell immunoglobulin and ITIM domain protein (TIGIT). Separately, Junshi has in-licensed antibody “modules,” or Dotbodies, from Dotbio Pte. Ltd. for use in oncology and the development of several multispecific antibodies.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Coherus BioSciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Coherus BioSciences is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,238 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Coherus BioSciences Patents

Coherus BioSciences has filed 91 patents.

The 3 most popular patent topics include:

  • Monoclonal antibodies
  • Biotechnology
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/31/2017

10/5/2021

Ureas, Biotechnology, Monoclonal antibodies, Molecular biology, Immunosuppressants

Grant

Application Date

10/31/2017

Grant Date

10/5/2021

Title

Related Topics

Ureas, Biotechnology, Monoclonal antibodies, Molecular biology, Immunosuppressants

Status

Grant

Coherus BioSciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Coherus BioSciences Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.